TRANSFORM Primary Analysis and Indirect Comparison of Liso-cel to Axi-cel

TRANSFORM Primary Analysis and Indirect Comparison of Liso-cel to Axi-cel

LBCL 2022 - Year in Review

Dr Jeremy S. Abramson analyzes data from the primary analysis of the TRANSFORM study and a matching-adjusted indirect comparison of liso-cel to axi-cel for the second-line treatment of primary refractory or early relapsed LBCL.

Related Items

OUTREACH Primary Analysis and Patient-Reported Outcomes

LBCL 2022 - Year in Review

OUTREACH Study Found Outpatient Monitoring for Liso-cel to Be Feasible

LBCL 2022 - Year in Review

Patient-Reported Outcomes and Health-Related Quality of Life from the OUTREACH Study

LBCL 2022 - Year in Review

Phase 1 CARBON Study Demonstrated Clinical Benefits with Allogeneic CAR-T Therapy CTX110 in Patients with R/R LBCL

LBCL 2022 - Year in Review

Long-Term Survival Following Relapse or Progression Post‒CAR-T in Patients with R/R LBCL Based on Real-World Data

LBCL 2022 - Year in Review

Effectiveness of CAR-T Therapy in Double-Hit and Double-Expressor Lymphomas

LBCL 2022 - Year in Review

ZUMA-7 Subsequent Therapies and Real-World Outcomes of Axi-cel for LBCL by Race and Ethnicity

LBCL 2022 - Year in Review

Association of Metabolic Tumor Volume and Clinical Outcomes in the ZUMA-7 Study

LBCL 2022 - Year in Review

Outcomes of Subsequent Therapies Following Axi-cel for Second-Line Treatment of Relapsed or Refractory LBCL in the ZUMA-7 Study

LBCL 2022 - Year in Review

Real-World Outcomes of Axi-cel for LBCL by Race and Ethnicity

LBCL 2022 - Year in Review